News | September 05, 2025
FDA completes inspection at Biocon Biologics' facility in Bengaluru
The U.S. FDA issued a Form 483 with five observations
The U.S. FDA issued a Form 483 with five observations
The medicine was well tolerated, with no unexpected safety issue
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
